Breaking News Instant updates and real-time market news.

EPZM

Epizyme

$16.25

0.4 (2.52%)

08:55
05/17/18
05/17
08:55
05/17/18
08:55

Epizyme to hold a conference call

Management discusses recent corporate updates and tazemetostat clinical data that will be presented at upcoming medical conferences, including ASCO, on a conference call to be held on May 17 at 9:30 am. Webcast Link

  • 17

    May

  • 18

    May

EPZM Epizyme
$16.25

0.4 (2.52%)

04/24/18
RHCO
04/24/18
NO CHANGE
Target $20
RHCO
Buy
Epizyme price target lowered to $20 from $27 at SunTrust
SunTrust analyst Peter Lawson lowered his price target on Epizyme to $20, saying that while the FDA hold on the tazemetostat trial should be brief, the 20% decline in the stock price afterhours justifies a more conservative target. In light of the hold, Lawson adds that he is also reducing his probability of success for tazemetostat to 60% from 65% and penetration to 75% from 85% in EZH2 mutant FL, while also reducing the probability of success in INI1-negative solid tumors to 60% from 85% and the penetration to 75% from 85%. The analyst keeps his Buy rating on Epizyme.
04/24/18
JMPS
04/24/18
NO CHANGE
Target $28
JMPS
Outperform
Epizyme hold news has 'number of mitigating factors,' says JMP Securities
JMP Securities analyst Michael GKing noted the FDA has issued a partial clinical hold for clinical trials evaluating Epizyme's tazemetostat, but he sees "a number of mitigating factors" to this negative news. Those include the fact that the Phase 2 FL and DLBCL trials are mostly enrolled and that the Phase 2 study in mesothelioma and epithelioid sarcoma are already fully enrolled. He sees it making sense that the FDA would issue a hold "out of an abundance of caution," given the pediatric indication, but he maintains an Outperform rating and $28 price target on Epizyme shares.
04/24/18
JEFF
04/24/18
NO CHANGE
Target $27
JEFF
Buy
Epizyme shares will bounce back, says Jefferies
Jefferies analyst Michael Yee says that while the partial clinical hold is a bad headline, shares of Epizyme (EPZM) will bounce back like Cellectis (CLLS), Juno and others did when they modified the protocol and trial brochures to get back up and running. After speaking to management, Yee thinks Epizyme's partial clinical hold will be lifted in a few months. Until then, however, the shares could be in the penalty box, the analyst tells investors in a research note. He keeps a Buy rating on Epizyme with a $27 price target.
04/24/18
ROTH
04/24/18
NO CHANGE
Target $24
ROTH
Buy
Epizyme clinical hold temporary, says Roth Capital
Roth Capital analyst Jotin Marango believes Epizyme's partial clinical hold is temporary. While the case of secondary lymphoma raises some doubts on tazemetostat's prospects in front-line, the analyst believes its clinical and commercial value in R/R disease remains intact. Marango reiterates a Buy rating and $24 price target on the shares.

TODAY'S FREE FLY STORIES

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.